JP Morgan Rates Genmab A (GMAB) Overweight

JP Morgan upgraded Genmab A (NASDAQ: GMAB) to an Overweight rating on October 26, 2026. This change reflects the firm's positive outlook on the company's potential for growth and profitability. The rating update was made on the same day as the event close, which saw Genmab shares at $44.82.

Genmab has been showing strong performance in the biotechnology sector, particularly with its antibody-based treatments for cancer. The company is known for its marketed products EPKINLY and TEPKINLY, which are used for various types of lymphoma, and Tivdak for cervical cancer. This upgrade comes as the stock has been trending above its moving averages, indicating solid momentum in the market.

GMAB Genmab A

$44.71 ▲ +40.51% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Other Institutional Activity in Genmab A

Several other institutional investors have recently made moves in Genmab A. Paradigm Biocapital Advisors LP increased its holdings by 5,165,449 shares, bringing its total to 13,133,131 shares valued at approximately $588.6 million. Meanwhile, Deerfield Management Company, L.P. also saw a significant increase, adding 4,403,015 shares for a total of 6,865,000 shares worth around $307.7 million. In contrast, Orbis Allan Gray Ltd reduced its stake by 1,557,548 shares, resulting in a total of 11,368,161 shares valued at about $509.5 million.

Genmab A Stock Up 12.0%

As of October 26, 2026, Genmab shares were recently trading around $44.79, which is about equal to the closing price of $44.82 on the same day. The stock is currently above its 50-day moving average by 27.2% and its 200-day moving average by 49.0%. Additionally, it is trading just above its 52-week high of $44.34, showing strong investor interest.

Recent Earnings

Genmab reported trailing twelve-month revenue of approximately $4.13 billion, reflecting a year-over-year revenue growth of 24.9%. The company's net margin stands at 19.1%, and its return on equity is 14.0%. The next earnings report is scheduled for November 5, 2026, which will provide further insight into its financial performance.

Analysts Set New Price Targets

On October 26, 2026, JP Morgan upgraded Genmab to an Overweight rating, although no new price target was set. Earlier, on October 5, 2026, Guggenheim maintained its Buy rating with a price target of $54.00, while Truist Securities also maintained a Buy rating with a target of $45.00. The consensus among analysts indicates a strong buy recommendation, with a mean price target of $45.95.

About Genmab A

Genmab A/S is a biotechnology company based in Copenhagen, Denmark. It develops and markets antibody-based products aimed at treating cancer and other diseases. With a focus on innovative treatments, Genmab has made significant strides in the biotechnology sector, which is reflected in the recent upgrades and positive analyst ratings.

Bottom Line

Investors should keep an eye on Genmab's upcoming earnings report on November 5, 2026, for further financial insights. The recent upgrade from JP Morgan adds to a growing consensus of confidence among analysts regarding Genmab's future performance.